Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and @entity5 . The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in @entity2615 ( @entity2615 ). Four groups of subjects were studied: 93 malignant @entity2615 @entity1 , 33 primary @entity1149 @entity1 , 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in @entity2615 @entity1 (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean+2SD of PDGF-AB in healthy controls, 43% of @entity2615 @entity1 showed positive PDGF-AB levels. Survival was evaluated in 82 @entity2615 @entity1 . At the end of the follow-up (median 9.8 months) 80.5% of @entity1 had died. Median survival was 13.1 and 7.9 months for @entity1 with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR=1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for @entity2615 .

Serum PDGF-AB in XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['pleural tumors'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non small cell lung cancer'] @entity2615 :: ('MESH:D008654', 'Disease') :: ['PM', 'pleural mesothelioma']
@entity2615 :: (MESH:D008654,Disease) :: ['pleural mesothelioma']
